Highlights from the September 2018 Issue
Editor’s Note: We asked authors of Original Investigations to provide short nontechnical summaries that would briefly summarize what inspired their study, the basic approach taken, what was learned, and why it matters. We hope our readers will find this valuable in helping them keep up with the latest research in the field of nephrology. From the September 2018 issue:
Congophilic Fibrillary Glomerulonephritis: A Case Series by Mariam P. Alexander et al
From the authors: Congo red stain has traditionally been utilized in distinguishing fibrillary glomerulonephritis (GN) from amyloidosis. In this study, we describe a subset of fibrillary GN which demonstrates variably positive staining with Congo red. The proteomic biochemical signature of amyloid was not detected in any of these cases. Instead, all showed overabundance of DNAJB9, a recently discovered specific marker for fibrillary GN. When faced with a suspected case of fibrillary GN with congophilic deposits which is a diagnostic challenge, we recommend the use of DNAJB9 immunohistochemistry and/or mass spectrometry to distinguish fibrillary GN from amyloidosis.
Editorial The Interpretation of Congophilia in Tissue Biopsies: Caution Required by Maria M. Picken [FREE]
Blog Post #PathPointer: Congo Red-Positive Always Means Amyloid Deposits, Right? by Timothy Yau [FREE]
A Comparative Study of Carvedilol Versus Metoprolol Initiation and 1-Year Mortality Among Individuals Receiving Maintenance Hemodialysis by Magdalene M. Assimon et al
From the authors: Carvedilol and metoprolol are the most common beta-blockers prescribed to US hemodialysis patients. Key differences in how these medications work and are eliminated from the body may alter their risk-benefit profiles in the hemodialysis population. Carvedilol causes blood vessels to dilate or widen, but metoprolol does not. Metoprolol is removed from the body by the hemodialysis procedure, but carvedilol is not. This observational study of over 27,000 hemodialysis patients found that individuals who started carvedilol therapy had higher rates of 1-year all-cause and cardiovascular mortality compared to individuals who started metoprolol therapy. It also showed that individuals who started carvedilol therapy experienced low blood pressure during dialysis treatments more often during follow-up compared to individuals who started metoprolol therapy. These findings suggest that medical providers should consider the properties of carvedilol and metoprolol along with patient blood pressure histories when prescribing beta-blockers to individuals receiving maintenance hemodialysis.
Editorial Heterogeneity in Outcomes Among β-Blockers Elucidated by Intradialytic Data by Chandan Vangala and Wolfgang C. Winkelmayer [FREE]
CKD Self-management: Phenotypes and Associations With Clinical Outcomes by Sarah J. Schrauben et al [FREE]
From the authors: In the effort to slow chronic kidney disease (CKD) progression and its complications, patients need to engage in healthy self-management behaviors. As CKD patients likely engage only in certain behaviors, the clustering of behaviors might associate with improved or worse clinical outcomes. This study assessed for clusters of behavior engagement among CKD patients, the association of these clusters with clinical outcomes, as well assessed for predictors of the behavior clusters. We used a specific clustering statistical technique to identify clusters of behavior engagement and discovered three clusters (or phenotypes) of behavior engagement among those with diabetes and without diabetes. The phenotypes with more recommended healthy behaviors was associated with better clinical outcomes than those with less healthy behaviors.
Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Multicenter Risk Assessment Study in Chinese Patients by Jingyuan Xie et al
From the authors: Only a subgroup of IgA nephropathy (IgAN) patients will progress to end-stage kidney disease (ESKD). Accurate estimation of kidney failure risk at 5 or 10 years after diagnosis is critically important for prognostication and patient counseling. This study provides analyses of a large cohort of IgAN patients to formulate accurate equations for ESKD risk prediction at time of renal biopsy implemented to diagnose IgAN. Among the total of 2,155 patients recruited for this study, 212 developed ESKD during the mean follow-up period of 52 months. The best clinical predictors of ESKD included age, gender, eGFR, hemoglobin, and urine protein. The best predictive model that combined both clinical and histology variables included age, eGFR, and the Oxford-M and T scores. The kidney failure risk prediction equations for calculating the probability of ESKD over 5 and 10 years were established and validated. The proposed prediction equations are simple and easy to implement in clinical practice.
Blood Lead Levels and Decreased Kidney Function in a Population-Based Cohort by Florencia Harari et al [OPEN ACCESS]
From the authors: It is not clear whether lead at low levels of exposure can affect the kidneys. Therefore, in the present study we used data from a sample of the general population in Sweden to investigate this. The exposure to lead was assessed by measuring the lead concentrations in blood. We estimated the kidney function using well-established equations and also assessed chronic kidney disease (CKD) diagnoses from a national medical registry. We found that higher lead concentrations in blood were associated with worse of kidney function as well as with increased risk of CKD. These findings suggest that reducing exposure to low levels of lead may reduce the burden of kidney disease and its associated health problems.
Blog Post Lead Burns Red and Makes You Dead by Timothy Yau [FREE]
Evolution of Echocardiographic Measures of Cardiac Disease From CKD to ESRD and Risk of All-Cause Mortality: Findings From the CRIC Study by Nisha Bansal et al
From the authors: Heart disease is common in patients with kidney disease. However, less is known about the natural history of heart disease as kidney function worsens. In this study, we evaluated the change in cardiac structure and function as patients transitioned from chronic kidney disease (CKD) to end-stage renal disease (ESRD). We hypothesized that there would be significant worsening of cardiac disease during this transition and that those patients with deterioration of cardiac disease would have worse outcomes after dialysis initiation. We found that among 417 patients with CKD there was a worsening in two measures of left ventricular contractility (ejection fraction and end-systolic volume)as patients progressed to ESRD necessitating dialysis. This worsening in left ventricular contractility was linked with higher risk of death after dialysis initiation. In contrast, there were improvement in other aspects of cardiac structure and function. These results suggest that clinically meaningful echocardiogram parameters are not fixed, but rather progress or regress even in advanced stages of CKD. These data suggest there are opportunities for intervention during the transition from CKD to dialysis initiation to reduce the risk of mortality and cardiovascular disease.
Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1 by Nadia Ayasreh et al
On the Cover: This photograph of Creede, Colorado was taken in 1942, when the manufacturing demands of World War II called upon the town’s metal mines to increase their productivity. Former mining towns like Creede have needed to deal with toxic waste runoff, laden with heavy metals such as lead, cadmium, and zinc, that contaminate rivers, aquifers, and other water supplies. In this month’s issue of AJKD, Florencia Harari and colleagues report that higher lead concentrations in blood are associated with worse kidney function as well as an increased risk of chronic kidney disease.
“Old lead mines…” Photo by Andreas Feininger, obtained from the Library of Congress, Prints & Photographs Division, Farm Security Administration/Office of War Information Collection [reproduction number LC-DIG-fsac-1a34856].
Leave a Reply